title: Efficacy of subgingivally delivered simvastatin in the treatment of patients with type 2 diabetes and chronic periodontitis: a randomized double-masked controlled clinical trial.
abstract: BACKGROUND
  Simvastatin (SMV) is a specific competitive inhibitor of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase. Recently, it has been reported that statins promote bone formation. The present study is designed to investigate the effectiveness of 1.2% SMV in an indigenously prepared, biodegradable, controlled-release gel as an adjunct to scaling and root planing (SRP) in the treatment of patients with type 2 diabetes and chronic periodontitis (CP).
  
  
  METHODS
  Thirty-eight patients were categorized into two treatment groups: SRP plus 1.2% SMV and SRP plus placebo. Clinical parameters were recorded at baseline before SRP and at 3, 6, and 9 months; they included modified sulcus bleeding index (mSBI), probing depth (PD), and clinical attachment level (CAL). At baseline and after 6 and 9 months, radiologic assessment of intrabony defect (IBD) fill was done using computer-aided software.
  
  
  RESULTS
  Mean PD reduction and mean CAL gain were found to be greater in the SMV group than the placebo group at 3, 6, and 9 months. Furthermore, significantly greater mean percentage of bone fill was found in the SMV group (32.64% ± 12.90%) compared to the placebo group (4.22% ± 9.75%) after 9 months.
  
  
  CONCLUSIONS
  There was a greater decrease in mSBI and PD and more CAL gain with significant IBD fill at sites treated with SRP plus locally delivered SMV in patients with type 2 diabetes and CP.
authors.affiliation: Department of Periodontics, Government Dental College and Research Institute, Bangalore, India. periodonticsgdcri@gmail.com
authors.forename: A R
authors.initials: AR
authors.lastname: Pradeep
authors.forename: Nishanth S
authors.initials: NS
authors.lastname: Rao
authors.forename: Pavan
authors.initials: P
authors.lastname: Bajaj
authors.forename: Minal
authors.initials: M
authors.lastname: Kumari
mesh_terms: D000328:Adult; D016301:Alveolar Bone Loss / Q000145:classification / Q000188:drug therapy; D055113:Chronic Periodontitis / Q000150:complications / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D012534:Dental Scaling / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010012:Osteogenesis / Q000187:drug effects; D017622:Periodontal Attachment Loss / Q000145:classification / Q000188:drug therapy; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000145:classification / Q000188:drug therapy; D010919:Placebos; D016745:Root Planing / Q000379:methods; D019821:Simvastatin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010919:Placebos; D019821:Simvastatin